News & Topics Past News
2016.02.10
SymBio's Long Range Plan: FY2016 to FY2018
2016.02.10
Summary of Financial Statements for the Fiscal Year Ended December 31, 2015[Japanese GAAP] (Non-consolidated)
2016.02.10
Notice Concerning Non-operating Expenses
2016.02.08
SymBio and Teikyo Heisei University enter into a Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
2016.02.04
Assessment Status of Bendamustine in Europe
2015.12.28
SymBio starts Global Phase 3 Trial for IV Rigosertib
2015.12.24
SymBio Files Supplemental NDA for TREAKISYM® in First-Line Low-grade NHL and MCL
2015.12.24
SymBio Files Supplemental NDA for TREAKISYM® in Chronic Lymphocytic Leukemia (Additional Indication)
2015.12.24
SymBio Files Supplemental NDA for TREAKISYM® in a 25mg Vial (Different Strength)
2015.12.08
Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
2015.12.08
Onconova Therapeutics Announces Enrollment of First Patient in Global Phase 3 Trial for IV Rigosertib
2015.12.07
Analyst Report: Shared Research updates the report
2015.12.07
Start of Japan Phase I Combination Clinical Trial of Oral Rigosertib and Azacytidine in Higher-risk MDS
2015.11.30
Analyst Report: Edison updates the report
2015.11.24
SymBio Partner Announces European Approval of IONSYS®
2015.11.06
Analyst Report: Shared Research updates the report
2015.11.06
Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
2015.11.06
Notice Concerning Non-operating Expenses
2015.10.30
Completion of Japan Phase 1 Clinical Trial for IV Rigosertib in MDS